Thiazolidinedione and metformin use and the risk of benign prostate hyperplasia in veterans with diabetes mellitus

Journal of Men's Health

Volumn 11, Issue 4, 2014, Pages 157-162

  Murff, Harvey J ^a,b   Roumie, Christianne L ^a,b   Greevy, Robert A ^a,b   Grijalva, Carlos G ^a,b   Hung, Adrianna H ^a,b   Liu, Xulei ^a,b   Griffin, Marie R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Benign prostatic hyperplasia; Diabetes mellitus; Metformin; Thiazolidinediones

Indexed keywords

ALFUZOSIN; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; GLIBENCLAMIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PRAZOSIN; ROSIGLITAZONE; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE SEVERITY; DRUG SAFETY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VETERAN;

EID: 84911869595     PISSN: 18756867     EISSN: 18756859     Source Type: Journal    
DOI: 10.1089/jomh.2014.0051     Document Type: Article

References (30)

1. Di Silverio F, Gentile V, De Matteis A, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis. Eur Urol 2003;43:164-175.
2. Roehrborn CG, Kaplan SA, Noble WD, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: Results from the MTOPS study. J Urol 2005;173:346.
3. Schenk JM, Kristal AR, Neuhouser ML, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2010;171:571-582.
4. Rohrmann S, De Marzo AM, Smit E, et al. Serum Creactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005;62:27-33.
5. Stamatiou K, Lardas M, Kostakos E, et al. The impact of diabetes type 2 in the pathogenesis of benign prostatic hyperplasia: A review. Adv Urol 2009:818965.
6. Barni T, Vannelli BG, Sadri R, et al. Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: Gene expression and its cellular localization. J Clin Endocrinol Metab 1994;78:778- 783.
7. Cohen P, Peehl DM, Baker B, et al. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1994;79:1410-1415.
8. Jiang M, Strand DW, Franco OE, et al. PPARgamma: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation 2011;82:220- 236.
9. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106-1118.
10. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-361.
11. Jiang M, Fernandez S, Jerome WG, et al. Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. Cell Death Differ 2010;17:469-481.
12. Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate 2010;70:79-89.
13. American Diabetes Association. Executive summary: Standards of medical care in diabetes-2012. Diabetes Care 2012;35:S4-S10.
14. Germeyer A, Jauckus J, Zorn M, et al. Metformin modulates IL-8, IL-1beta, ICAM and IGFBP-1 expression in human endometrial stromal cells. Reprod Biomed Online 2011;22:327-334.
15. Takemura Y, Osuga Y, Yoshino O, et al. Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J Clin Endocrinol Metab 2007;92:3213-3218.
16. Penna G, Fibbi B, Amuchastegui S, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 2009;182:4056-4064.
17. Fibbi B, Penna G, Morelli A, et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010;33:475-488.
18. Penna G, Mondaini N, Amuchastegui S, et al. Seminal plasma cytokines and chemokines in prostate inflammation: Interleukin 8 as a predictive biomarker in chronic prostatitis/ chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007;51:524-533.
19. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: A new perspective for an old antidiabetic drug? Mol Cancer Ther 2010;9:1092-1099.
20. Hung AM, Roumie CL, Greevy RA, Liu X, et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int 2012;81:698-706.
21. Roumie CL, Hung AM, Greevy RA, Grijalva CG, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study. Ann Intern Med 2012;157:601- 610.
22. St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006;164:760-768.
23. Sutcliffe S, Grubb Iii RL, Platz EA, et al. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int 2012;110:1050-1059.
24. Araki T, Yokoyama T, Kumon H. Effectiveness of a nonsteroidal anti-inflammatory drug for nocturia on patients with benign prostatic hyperplasia: a prospective nonrandomized study of loxoprofen sodium 60mg once daily before sleeping. Acta Med Okayama 2004;58:45-49.
25. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-86.
26. Standiford TJ, Keshamouni VG, Reddy RC. Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair. ProcAmThoracSoc 2005;2:226-231.
27. Vikram A, Jena G, Ramarao P. Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia. Br J Pharmacol 2010;161:1708-1721.
28. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3:1451-1461.
29. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Antidiabetic medication and prostate cancer risk: a population-based casecontrol study. Am J Epidemiol 2008;168:925-931.
30. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: Results from a population-based casecontrol study. Cancer Causes Control 2009;20:1617-1622.